Citation Information :
Havaldar AA, Lobo V, Sushmitha EC, Kumar MV, Raj JM, Thomas T. Role of Biomarkers and Its Trend to Predict the Outcome of COVID-19 Patients: A Retrospective Study. Indian J Crit Care Med 2022; 26 (9):1031-1035.
Background: Biomarkers have been extensively studied and used in the diagnosis and management of various diseases. The trend of biomarkers helps in prognosticating and managing critically ill patients. In resource-limited settings, the availability and feasibility of using these biomarkers are challenging. Our study aimed to see the trend of biomarkers and their effect on intensive care unit (ICU) mortality in coronavirus disease-2019 (COVID-19) patients.Materials and methods: A retrospective observational study was done from 1 April 2020 to 30 September 2020. The primary objective was to evaluate the trend of biomarkers in patients with COVID-19 pneumonia and their effect on ICU mortality. The secondary objectives were the duration of mechanical ventilation and length of ICU stay. Results: A total of 380 patients were included. The mean age was 54.9 (SD = 11.1) and 67% were males. The mean age, acute physiology and chronic health evaluation II (APACHE II) score was 29.54 (5.8). Among the biomarkers, total count (TC), ferritin, and procalcitonin (PCT) were higher in non-survivors than in survivors in bivariate analysis. The final multivariable logistic regression model showed age, APACHE II score, length of ICU stay, neutrophil:lymphocyte (NL) ratio, and ferritin as covariates. Among these variables, ferritin was the only biomarker [odds ratio (OR): 1.80, 95% confidence interval (CI) 1.17–2.77] with the APACHE II score (OR: 1.15, 95% CI 1.01–1.30) found to be significant. Conclusion: Ferritin was the only significant biomarker with higher values in non-survivors than in survivors. The trend of biomarkers was not found to be useful in predicting outcome of the patients.
Aronson JK, Ferner RE. Biomarkers: A general review. Current protocols in pharmacology 2017;76(1):9–23. DOI: 10.1002/cpph.19.
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 2020;57(6):389–399. DOI: 10.1080/10408363.2020.1770685.
Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez–Fernandez C, et al. Predicting disease severity and outcome in COVID-19 patients: A review of multiple biomarkers. Arch Pathol Lab Med 2020;144(12):1465–1474. DOI: 10.5858/arpa.2020-0471-SA.
Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, et al. Inflammatory biomarker trends predict respiratory decline in COVID-19 patients. Cell Rep Med 2020;1(8):100144. DOI: 10.1016/j.xcrm.2020.100144.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus– infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061– 1069. DOI: 10.1001/jama.2020.1585.
Danwang C, Endomba FT, Nkeck JR, Wouna DL, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomarker Res 2020; 8:37. DOI: 10.1186/s40364-020-00217-0.
Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis. BMJ Evid Based Med 2021;26(3):107–108. DOI: 10.1136/bmjebm-2020-111536.
Welder D, Jeon–Slaughter H, Ashraf B, Choi SH, Chen W, Ibrahim I, et al. Immature platelets as a biomarker for disease severity and mortality in COVID-19 patients. Br J Haematol 2021;194(3):530–536. DOI: 10.1111/bjh.17656.
Karampoor S, Zahednasab H, Farahmand M, Mirzaei R, Zamani F, Tabibzadeh A, et al. A possible pathogenic role of Syndecan-1 in the pathogenesis of coronavirus disease 2019 (COVID-19). Int Immunopharmacol 2021;97:107684. DOI: 10.1016/j.intimp. 2021.107684.
Ahmed S, Jafri L, Hoodbhoy Z, Siddiqui I. Prognostic value of serum procalcitonin in COVID-19 patients: A systematic review. Indian J Crit Care Med 2021;25(1):77–84. DOI: 10.5005/jp-journals- 10071-23706.
Ahmed S, Mansoor M, Shaikh MS, Siddiqui I. Presepsin as a predictive biomarker of severity in COVID-19: A systematic review. Indian J Crit Care Med 2021;25(9):1051. DOI: 10.5005/jp-journals-10071-23967.
Hashem MK, Khedr EM, Daef E, Mohamed–Hussein A, Mostafa EF, Hassany SM, et al. Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet- to-lymphocyte ratio, and D-dimer. Egypt J Bronchol 2021;15(1):1–9. DOI: 10.1186/s43168-021-00075-w.
Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care 2022;67:172–181. DOI: 10.1016/j.jcrc.2021.09.023.
Deng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clín 2021;156(7):324–331. DOI: 10.1016/j.medcli.2020.11.030.